K. Thomas Robbins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
K. Thomas Robbins has a total of 437 co-authors. Here are the top co-authors by number of shared publications:
Muthuswamy Dhiwakar
6 shared publicationsFrancisco Vieira
4 shared publicationsJames Malone
4 shared publicationsKrishna Rao
4 shared publicationsOhad Ronen
Division of Otolaryngology – Head & Neck Surgery, Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois
3 shared publicationsParvesh Kumar
3 shared publications
Latest Publications
- 1 January 2015
- Published by IMR Press in Frontiers in Bioscience-Elite
- Vol. 7 (1) , 66-76
HPV and CSC in HNSCC cisplatin resistance
Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is offered by a distinct disease entity in HNSCC – HPV+ OPSCC. It responds far more favorably to cisplatin than non-HPV driven HNSCC. Another intriguing aspect of head and neck cancer biology is the emergence of the CD44+ cancer stem cell - the tumor initiating population that in all likelihood is the root cause of therapeutic resistance. The critical question is, are there any differences between the CD44+ CSC population of an HPV+ OPSCC and a non-HPV HNSCC? In this regard, the inverse relation between EGFR levels and HPV status in OPSCC may be a common thread that connects the better response rates of HPV+ OPSCC with the contribution of CD44+ stem cells of HNSCC to chemoresistance.
- 1 January 2015
- Published by IMR Press in Frontiers in Bioscience-Elite
- Vol. 7 (1) , 66-76
HPV and CSC in HNSCC cisplatin resistance
Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is offered by a distinct disease entity in HNSCC – HPV+ OPSCC. It responds far more favorably to cisplatin than non-HPV driven HNSCC. Another intriguing aspect of head and neck cancer biology is the emergence of the CD44+ cancer stem cell - the tumor initiating population that in all likelihood is the root cause of therapeutic resistance. The critical question is, are there any differences between the CD44+ CSC population of an HPV+ OPSCC and a non-HPV HNSCC? In this regard, the inverse relation between EGFR levels and HPV status in OPSCC may be a common thread that connects the better response rates of HPV+ OPSCC with the contribution of CD44+ stem cells of HNSCC to chemoresistance.
- 1 November 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (11) , 1185-1189
Efficacy of super-selective neck dissection following chemoradiation for advanced head and neck cancer
- 1 November 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (11) , 1185-1189
Efficacy of super-selective neck dissection following chemoradiation for advanced head and neck cancer
- 2 February 2012
- Published by Wiley in Head & Neck
- Vol. 35 (6) , E194-E196
Mediastinal goiter presenting with ventricular tachycardia
Background: We report a rare case of a mediastinal goiter confined to the thoracic inlet and cavity presenting with ventricular tachycardia as the sole clinical manifestation.Methods and Results: The patient did not have any of the typical features of a mediastinal goiter such as neck swelling, dysphagia, or respiratory difficulty, but instead had spontaneous onset of wide‐complex tachycardia requiring emergency treatment. This atypical presentation led to initial misinterpretation of imaging studies and delayed diagnosis of the mediastinal mass. The large, completely intrathoracic thyroid goiter abutted the cardiac muscle and required a combined transcervical and median sternotomy approach for removal. The arrhythmia resolved postoperatively.Conclusion: To our knowledge, this case represents the first documented presentation of ventricular tachycardia as a unique and sole feature of mediastinal goiter. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
- 2 February 2012
- Published by Wiley in Head & Neck
- Vol. 35 (6) , E194-E196
Mediastinal goiter presenting with ventricular tachycardia
Background: We report a rare case of a mediastinal goiter confined to the thoracic inlet and cavity presenting with ventricular tachycardia as the sole clinical manifestation.Methods and Results: The patient did not have any of the typical features of a mediastinal goiter such as neck swelling, dysphagia, or respiratory difficulty, but instead had spontaneous onset of wide‐complex tachycardia requiring emergency treatment. This atypical presentation led to initial misinterpretation of imaging studies and delayed diagnosis of the mediastinal mass. The large, completely intrathoracic thyroid goiter abutted the cardiac muscle and required a combined transcervical and median sternotomy approach for removal. The arrhythmia resolved postoperatively.Conclusion: To our knowledge, this case represents the first documented presentation of ventricular tachycardia as a unique and sole feature of mediastinal goiter. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
- 28 June 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (S4) , S117
Mediastinal Goiter Presenting with Ventricular Tachycardia
- 28 June 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (S4) , S117
Mediastinal Goiter Presenting with Ventricular Tachycardia
- 5 April 2011
- Published by Wiley in Head & Neck
- Vol. 34 (2) , 188-193
Selective neck dissection as an early salvage intervention for clinically persistent nodal disease following chemoradiation
Background The aim of this study was to determine the efficacy of selective neck dissection (SND) performed for persistent nodal disease after chemoradiation. Methods Patients treated with definitive chemoradiation for squamous cell carcinoma of the head and neck who subsequently underwent SND for early salvage of clinically persistent nodal disease were evaluated. The primary outcome measure was regional disease control. Results A total of 62 patients underwent 69 SND procedures. The median time interval between completion of chemoradiation and neck dissection was 10 weeks. There was evidence of residual tumor in 32 neck dissection specimens (46%). Forty patients (65%) remained free of disease, whereas the remaining 22 patients (35%) developed a recurrence, among which 4 were regional. Of these, 3 occurred in the contralateral neck and only 1 occurred in the targeted (ipsilateral) neck. Conclusions SND is an effective early salvage intervention for persistent nodal disease in patients treated with chemoradiation. © 2011 Wiley Periodicals, Inc. Head Neck, 2012
- 5 April 2011
- Published by Wiley in Head & Neck
- Vol. 34 (2) , 188-193
Selective neck dissection as an early salvage intervention for clinically persistent nodal disease following chemoradiation
Background The aim of this study was to determine the efficacy of selective neck dissection (SND) performed for persistent nodal disease after chemoradiation. Methods Patients treated with definitive chemoradiation for squamous cell carcinoma of the head and neck who subsequently underwent SND for early salvage of clinically persistent nodal disease were evaluated. The primary outcome measure was regional disease control. Results A total of 62 patients underwent 69 SND procedures. The median time interval between completion of chemoradiation and neck dissection was 10 weeks. There was evidence of residual tumor in 32 neck dissection specimens (46%). Forty patients (65%) remained free of disease, whereas the remaining 22 patients (35%) developed a recurrence, among which 4 were regional. Of these, 3 occurred in the contralateral neck and only 1 occurred in the targeted (ipsilateral) neck. Conclusions SND is an effective early salvage intervention for persistent nodal disease in patients treated with chemoradiation. © 2011 Wiley Periodicals, Inc. Head Neck, 2012
- 10 November 2010
- Published by Wiley in Head & Neck
- Vol. 33 (8) , 1099-1105
Efficacy of selective neck dissection for nodal metastasis with involvement of nonlymphatic structures
- 10 November 2010
- Published by Wiley in Head & Neck
- Vol. 33 (8) , 1099-1105
Efficacy of selective neck dissection for nodal metastasis with involvement of nonlymphatic structures
- 24 August 2010
- Published by Wiley in Head & Neck
- Vol. 33 (5) , 603-609
Feasibility of submandibular gland preservation in neck dissection: A prospective anatomic‐pathologic study
Background.: The submandibular gland is commonly removed during neck dissection involving sublevel IB. However, removal reduces basal salivary secretion and therapeutic options for minimizing xerostomia. The purpose of this study was to determine whether all lymph nodes in sublevel IB can be extirpated without removing the submandibular gland.Methods.: Twenty consecutive patients undergoing 33 neck dissections were prospectively enrolled. Sublevel IB dissection was performed by 3 sequential steps: (1) removal of targeted lymph node groups (preglandular and postglandular, prevascular and postvascular), (2) removal of submandibular gland, and (3) removal of residual lymphoadipose tissue in the surgical bed.Results.: Complete removal of lymph nodes in sublevel IB was achieved before excising the submandibular gland in all of the 30 eligible neck dissections. The submandibular gland and the surgical bed contained no residual lymph nodes.Conclusion.: In suitable cases, it is technically feasible to remove all lymph nodes in sublevel IB and preserve the submandibular gland. © 2010 Wiley Periodicals, Inc. Head Neck, 2011
- 24 August 2010
- Published by Wiley in Head & Neck
- Vol. 33 (5) , 603-609
Feasibility of submandibular gland preservation in neck dissection: A prospective anatomic‐pathologic study
Background.: The submandibular gland is commonly removed during neck dissection involving sublevel IB. However, removal reduces basal salivary secretion and therapeutic options for minimizing xerostomia. The purpose of this study was to determine whether all lymph nodes in sublevel IB can be extirpated without removing the submandibular gland.Methods.: Twenty consecutive patients undergoing 33 neck dissections were prospectively enrolled. Sublevel IB dissection was performed by 3 sequential steps: (1) removal of targeted lymph node groups (preglandular and postglandular, prevascular and postvascular), (2) removal of submandibular gland, and (3) removal of residual lymphoadipose tissue in the surgical bed.Results.: Complete removal of lymph nodes in sublevel IB was achieved before excising the submandibular gland in all of the 30 eligible neck dissections. The submandibular gland and the surgical bed contained no residual lymph nodes.Conclusion.: In suitable cases, it is technically feasible to remove all lymph nodes in sublevel IB and preserve the submandibular gland. © 2010 Wiley Periodicals, Inc. Head Neck, 2011
- 22 April 2010
- Published by Wiley in Head & Neck
- Vol. 32 (6) , 820
Commentary
- Open Access
Intra‐arterial chemotherapy for head and neck cancer
Although it would appear that there is no difference in outcomes for intra‐arterial (IA) versus intravenous cisplatin chemoradiotherapy, one must consider the technique by which the tumors were infused. The authors used the less effective method of bilateral infusion in 58% of patients compared to <5% by us. This large difference could have affected the outcome thus leaving the value of IA cisplatin infusion in question.
Open AccessIntra‐arterial chemotherapy for head and neck cancer
Although it would appear that there is no difference in outcomes for intra‐arterial (IA) versus intravenous cisplatin chemoradiotherapy, one must consider the technique by which the tumors were infused. The authors used the less effective method of bilateral infusion in 58% of patients compared to <5% by us. This large difference could have affected the outcome thus leaving the value of IA cisplatin infusion in question.